Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
Dosimetry during peptide receptor radionuclide therapy (PRRT) has mainly focused on normal organs and less on the tumors. The absorbed dose in one target tumor per patient and several response related factors were assessed in 23 pancreatic neuroendocrine neoplasms (P-NENs) and 25 small-intestinal NE...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/5/962 |
id |
doaj-fa7ea4b9b5f546c5a6d343e91103d04a |
---|---|
record_format |
Article |
spelling |
doaj-fa7ea4b9b5f546c5a6d343e91103d04a2021-02-26T00:03:33ZengMDPI AGCancers2072-66942021-02-011396296210.3390/cancers13050962Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine NeoplasmsUlrika Jahn0Ezgi Ilan1Mattias Sandström2Mark Lubberink3Ulrike Garske-Román4Anders Sundin5Department of Surgical Sciences, Radiology & Molecular Imaging, Uppsala University Hospital, SE-751 85 Uppsala, SwedenDepartment of Surgical Sciences, Radiology & Molecular Imaging, Uppsala University Hospital, SE-751 85 Uppsala, SwedenDepartment of Surgical Sciences, Radiology & Molecular Imaging, Uppsala University Hospital, SE-751 85 Uppsala, SwedenDepartment of Surgical Sciences, Radiology & Molecular Imaging, Uppsala University Hospital, SE-751 85 Uppsala, SwedenDepartment of Surgical Sciences, Radiology & Molecular Imaging, Uppsala University Hospital, SE-751 85 Uppsala, SwedenDepartment of Surgical Sciences, Radiology & Molecular Imaging, Uppsala University Hospital, SE-751 85 Uppsala, SwedenDosimetry during peptide receptor radionuclide therapy (PRRT) has mainly focused on normal organs and less on the tumors. The absorbed dose in one target tumor per patient and several response related factors were assessed in 23 pancreatic neuroendocrine neoplasms (P-NENs) and 25 small-intestinal NEN (SI-NENs) during PRRT with <sup>177</sup>Lu-DOTATATE. The total administered activity per patient was (mean ± standard error of mean (SEM) 31.8 ± 1.9 GBq for P-NENs and 36 ± 1.94 GBq for SI-NENs. The absorbed tumor dose was 143.5 ± 2 Gy in P-NENs, 168.2 ± 2 Gy in SI-NENs. For both NEN types, a dose–response relationship was found between the absorbed dose and tumor shrinkage, which was more pronounced in P-NENs. A significant drop in the absorbed dose per cycle was shown during the course of PRRT. Tumor vascularization was higher in P-NENs than in SI-NENs at baseline but equal post-PRRT. The time to progression (RECIST 1.1) was similar for patients with P-NEN (mean ± SEM 30 ± 1 months) and SI-NEN (33 ± 1 months). In conclusion, a dose response relationship was established for both P-NENs and SI-NENs and a significant drop in the absorbed dose per cycle was shown during the course of PRRT, which warrants further investigation to understand the factors impacting PRRT to improve personalized treatment protocol design.https://www.mdpi.com/2072-6694/13/5/962radionuclide therapytheranostics<sup>177</sup>Lu-DOTATATEPRRTsmall intestinal NENpancreatic NEN |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ulrika Jahn Ezgi Ilan Mattias Sandström Mark Lubberink Ulrike Garske-Román Anders Sundin |
spellingShingle |
Ulrika Jahn Ezgi Ilan Mattias Sandström Mark Lubberink Ulrike Garske-Román Anders Sundin Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms Cancers radionuclide therapy theranostics <sup>177</sup>Lu-DOTATATE PRRT small intestinal NEN pancreatic NEN |
author_facet |
Ulrika Jahn Ezgi Ilan Mattias Sandström Mark Lubberink Ulrike Garske-Román Anders Sundin |
author_sort |
Ulrika Jahn |
title |
Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms |
title_short |
Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms |
title_full |
Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms |
title_fullStr |
Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms |
title_full_unstemmed |
Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms |
title_sort |
peptide receptor radionuclide therapy (prrt) with <sup>177</sup>lu-dotatate; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-02-01 |
description |
Dosimetry during peptide receptor radionuclide therapy (PRRT) has mainly focused on normal organs and less on the tumors. The absorbed dose in one target tumor per patient and several response related factors were assessed in 23 pancreatic neuroendocrine neoplasms (P-NENs) and 25 small-intestinal NEN (SI-NENs) during PRRT with <sup>177</sup>Lu-DOTATATE. The total administered activity per patient was (mean ± standard error of mean (SEM) 31.8 ± 1.9 GBq for P-NENs and 36 ± 1.94 GBq for SI-NENs. The absorbed tumor dose was 143.5 ± 2 Gy in P-NENs, 168.2 ± 2 Gy in SI-NENs. For both NEN types, a dose–response relationship was found between the absorbed dose and tumor shrinkage, which was more pronounced in P-NENs. A significant drop in the absorbed dose per cycle was shown during the course of PRRT. Tumor vascularization was higher in P-NENs than in SI-NENs at baseline but equal post-PRRT. The time to progression (RECIST 1.1) was similar for patients with P-NEN (mean ± SEM 30 ± 1 months) and SI-NEN (33 ± 1 months). In conclusion, a dose response relationship was established for both P-NENs and SI-NENs and a significant drop in the absorbed dose per cycle was shown during the course of PRRT, which warrants further investigation to understand the factors impacting PRRT to improve personalized treatment protocol design. |
topic |
radionuclide therapy theranostics <sup>177</sup>Lu-DOTATATE PRRT small intestinal NEN pancreatic NEN |
url |
https://www.mdpi.com/2072-6694/13/5/962 |
work_keys_str_mv |
AT ulrikajahn peptidereceptorradionuclidetherapyprrtwithsup177supludotatatedifferencesintumordosimetryvascularityandlesionmetricsinpancreaticandsmallintestinalneuroendocrineneoplasms AT ezgiilan peptidereceptorradionuclidetherapyprrtwithsup177supludotatatedifferencesintumordosimetryvascularityandlesionmetricsinpancreaticandsmallintestinalneuroendocrineneoplasms AT mattiassandstrom peptidereceptorradionuclidetherapyprrtwithsup177supludotatatedifferencesintumordosimetryvascularityandlesionmetricsinpancreaticandsmallintestinalneuroendocrineneoplasms AT marklubberink peptidereceptorradionuclidetherapyprrtwithsup177supludotatatedifferencesintumordosimetryvascularityandlesionmetricsinpancreaticandsmallintestinalneuroendocrineneoplasms AT ulrikegarskeroman peptidereceptorradionuclidetherapyprrtwithsup177supludotatatedifferencesintumordosimetryvascularityandlesionmetricsinpancreaticandsmallintestinalneuroendocrineneoplasms AT anderssundin peptidereceptorradionuclidetherapyprrtwithsup177supludotatatedifferencesintumordosimetryvascularityandlesionmetricsinpancreaticandsmallintestinalneuroendocrineneoplasms |
_version_ |
1724250438126010368 |